tert-butyl 4-{2-[3-(hydroxymethyl)phenyl]-6-morpholin-4-yl-9H-purin-9-yl}piperidine-1-carboxylate | 1062204-86-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: tert-butyl 4-{2-[3-(hydroxymethyl)phenyl]-6-morpholin-4-yl-9H-purin-9-yl}piperidine-1-carboxylate
• 英文别名: tert-butyl 4-[2-[3-(hydroxymethyl)phenyl]-6-morpholin-4-ylpurin-9-yl]piperidine-1-carboxylate
• CAS: 1062204-86-7
• 化学式: C₂₆H₃₄N₆O₄
• 分子量: 494.594
• InChiKey: YPLLGJJEAPUBAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-{2-[3-(hydroxymethyl)phenyl]-6-morpholin-4-yl-9H-purin-9-yl}piperidine-1-carboxylate 在 三氟乙酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 [3-(6-morpholin-4-yl-9-piperidin-4-yl-9H-purin-2-yl)phenyl]methanol
  参考文献：
  名称：

  Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors

  摘要：

  This article describes the syntheses and SAR of a series of imidazolopyrimidine derivatives, which are evaluated as inhibitors of PI3-Kinase (PI3 K) and mTOR. These compounds were found to be ATP competitive with good tumor cell growth inhibition, and suppression of pathway specific biomakers such as phosphorylation of Akt at T308. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.057
• 作为产物：
  描述：

  tert-butyl 4-(2-chloro-6-morpholino-9H-purin-9-yl)piperidine-1-carboxylate 、 3-羟甲基苯硼酸 在 四(三苯基膦)钯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.25h， 生成 tert-butyl 4-{2-[3-(hydroxymethyl)phenyl]-6-morpholin-4-yl-9H-purin-9-yl}piperidine-1-carboxylate
  参考文献：
  名称：

  Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors

  摘要：

  This article describes the syntheses and SAR of a series of imidazolopyrimidine derivatives, which are evaluated as inhibitors of PI3-Kinase (PI3 K) and mTOR. These compounds were found to be ATP competitive with good tumor cell growth inhibition, and suppression of pathway specific biomakers such as phosphorylation of Akt at T308. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.057

文献信息

• IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS
  申请人：Bursavich Matthew Gregory

  公开号：US20080233127A1

  公开（公告）日：2008-09-25

  The present invention relates to Imidazolopyrimidine Analogs, methods of making Imidazolopyrimidine Analogs, compositions comprising an Imidazolopyrimidine Analog, and methods for treating or preventing a PI3K-related disorder comprising administering to a subject in need thereof an effective amount of an Imidazolopyrimidine Analog. The invention also relates to methods for treating or preventing mTOR-related disorders comprising administering to a subject in need thereof an effective amount of an Imidazolopyrimidine Analog.

  本发明涉及咪唑吡嘧啶类似物，制备咪唑吡嘧啶类似物的方法，包含咪唑吡嘧啶类似物的组合物，以及治疗或预防PI3K相关疾病的方法，包括向需要的受试者施用有效量的咪唑吡嘧啶类似物。该发明还涉及治疗或预防mTOR相关疾病的方法，包括向需要的受试者施用有效量的咪唑吡嘧啶类似物。
• p38 MAP KINASE INHIBITORS
  申请人：Chroma Therapeutics Limited

  公开号：EP2013175A1

  公开（公告）日：2009-01-14
• [EN] p38 MAP KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE-KINASE ASSOCIÉE AUX MEMBRANES p38
  申请人：CHROMA THERAPEUTICS LTD

  公开号：WO2007129040A1

  公开（公告）日：2007-11-15

  [EN] Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: (I), wherein: G is -N= or -CH=; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5 - 13 ring members; R6 is hydrogen or optionally substituted C1-C3 alkyl; P represents hydrogen and U represents a radical of formula (IA); or U represents hydrogen and P represents a radical of formula -A-(CH2)z-X1-L1-Y-NH-CHRiR2 wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members; z, Y, L1, and X1 are as defined in the specification; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; and R2 is the side chain of a natural or non-natural alpha amino acid.
  [FR] L'invention concerne des composés de formule (I) inhibiteurs de l'activité de la protéine-kinase associée aux membranes p38, et par conséquent utiles, entre autres, dans le traitement de troubles inflammatoires, tels que la polyarthrite rhumatoïde et la bronchopneumopathie chronique obstructive. Dans cette formule, G représente -N= ou -CH=; D représente un radical aryle ou hétéroaryle monocyclique ou bicyclique divalent éventuellement substitué possédant 5 à 13 chaînons cycliques; R6 représente un hydrogène ou un alkyle en C1-C3 éventuellement substitué; P représente un hydrogène et U représente un radical de formule (IA); ou U représente un hydrogène et P représente un radical de formule -A-(CH2)z-X1-L1-Y-NH-CHRiR2, dans cette formule A représente un radical carbocyclique ou hétérocyclique monocyclique ou bicyclique divalent éventuellement substitué possédant 5 à 13 chaînons cycliques; z, Y, L1, et X1 sont tels que définis dans la description; R1 représente un groupe d'acide carboxylique (-COOH), ou un groupe ester hydrolysable par une ou plusieurs enzymes estérases intracellulaires en un groupe d'acide carboxylique; et R2 représente une chaîne latérale d'un aminoacide alpha naturel ou non naturel.
• [EN] IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS<br/>[FR] ANALOGUES D'IMIDAZOLOPYRIMIDINE ET LEUR UTILISATION COMME INHIBITEURS DE PI3 KINASE ET DE MTOR
  申请人：WYETH CORP

  公开号：WO2008116129A2

  公开（公告）日：2008-09-25

  [EN] The present invention relates to Imidazolopyrimidine Analogs, methods of making Imidazolopyrimidine Analogs, compositions comprising an Imidazolopyrimidine Analog, and methods for treating or preventing a PI3K-related disorder comprising administering to a subject in need thereof an effective amount of an Imidazolopyrimidine Analog. The invention also relates to methods for treating or preventing mTOR -related disorders comprising administering to a subject in need thereof an effective amount of an Imidazolopyrimidine Analog.
  [FR] La présente invention concerne des angalogues d'imidazolopyrimidine, des procédés de préparation d'analogues d'imidazolopyrimidine, des compositions comprenant un analogue d'imidazolopyrimidine, et des procédés de traitement ou de prévention d'un trouble lié au PI3K comprenant l'administration à un sujet qui en a besoin d'une quantité efficace d'un analogue d'imidazolopyrimidine. L'invention concerne également un procédé de traitement ou de prévention de troubles liés au MTOR comprenant l'administration à un sujet qui en a besoin d'une quantité efficace d'analogue d'imidazolopyrimidine.
• Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors
  作者：Aranapakam M. Venkatesan、Christoph M. Dehnhardt、Zecheng Chen、Efren Delos Santos、Osvaldo Dos Santos、Matthew Bursavich、Adam M. Gilbert、John W. Ellingboe、Semiramis Ayral-Kaloustian、Gulnaz Khafizova、Natasja Brooijmans、Robert Mallon、Irwin Hollander、Larry Feldberg、Judy Lucas、Ker Yu、Jay Gibbons、Robert Abraham、Tarek S. Mansour

  DOI：10.1016/j.bmcl.2009.11.057

  日期：2010.1

  This article describes the syntheses and SAR of a series of imidazolopyrimidine derivatives, which are evaluated as inhibitors of PI3-Kinase (PI3 K) and mTOR. These compounds were found to be ATP competitive with good tumor cell growth inhibition, and suppression of pathway specific biomakers such as phosphorylation of Akt at T308. (C) 2009 Elsevier Ltd. All rights reserved.